Halozyme Therapeutics Inc - Asset Resilience Ratio

Latest as of September 2025: 12.71%

Halozyme Therapeutics Inc (HALO) has an Asset Resilience Ratio of 12.71% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Halozyme Therapeutics Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$282.30 Million

Cash + Short-term Investments

Total Assets

$2.22 Billion

All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2024)

This chart shows how Halozyme Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Halozyme Therapeutics Inc.

Liquid Assets Composition Over Time

This chart breaks down Halozyme Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Halozyme Therapeutics Inc (HALO) total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$282.30 Million	12.71%
Total Liquid Assets	$282.30 Million	12.71%

Asset Resilience Insights

Moderate Liquidity: Halozyme Therapeutics Inc has 12.71% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Halozyme Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Halozyme Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
PYC Therapeutics Ltd AU:PYC	Biotechnology	83.51%

Annual Asset Resilience Ratio for Halozyme Therapeutics Inc (2011–2024)

The table below shows the annual Asset Resilience Ratio data for Halozyme Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	23.27%	$480.22 Million	$2.06 Billion	+10.72pp
2023-12-31	12.56%	$217.63 Million	$1.73 Billion	+5.57pp
2022-12-31	6.98%	$128.60 Million	$1.84 Billion	-49.35pp
2021-12-31	56.34%	$622.20 Million	$1.10 Billion	+18.35pp
2020-12-31	37.99%	$220.31 Million	$579.92 Million	-15.22pp
2019-12-31	53.21%	$301.08 Million	$565.87 Million	-14.16pp
2018-12-31	67.37%	$296.59 Million	$440.25 Million	+9.58pp
2017-12-31	57.79%	$300.47 Million	$519.95 Million	+4.94pp
2016-12-31	52.85%	$138.22 Million	$261.51 Million	+17.07pp
2015-12-31	35.78%	$65.05 Million	$181.79 Million	-8.94pp
2014-12-31	44.73%	$74.23 Million	$165.98 Million	+1.36pp
2013-12-31	43.37%	$44.15 Million	$101.79 Million	--
2012-12-31	0.00%	$0.00	$134.73 Million	--
2011-12-31	0.00%	$0.00	$65.76 Million	--

pp = percentage points

About Halozyme Therapeutics Inc

NASDAQ:HALO USA Biotechnology

Market Cap

$12.49 Billion

Market Cap Rank

#2491 Global

#917 in USA

Share Price

$106.25

Change (1 day)

-1.57%

52-Week Range

$61.63 - $110.76

All Time High

$110.76